skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Refinado por: Nome da Publicação: Cancer Research remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
Material Type:
Artigo 		Adicionar ao Meu Espaço

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

WILHELM, Scott M ; CARTER, Christopher ; CAO, Yichen ; SHUJATH, Jaleel ; GAWLAK, Susan ; EVELEIGH, Deepa ; ROWLEY, Bruce ; LI LIU ; ADNANE, Lila ; LYNCH, Mark ; AUCLAIR, Daniel ; TAYLOR, Ian ; TANG, Liya ; GEDRICH, Rich ; VOZNESENSKY, Andrei ; RIEDL, Bernd ; POST, Leonard E ; BOLLAG, Gideon ; TRAIL, Pamela A ; WILKIE, Dean ; MCNABOLA, Angela ; HONG RONG ; CHEN, Charles ; XIAOMEI ZHANG ; VINCENT, Patrick ; MCHUGH, Mark

Cancer research (Chicago, Ill.), 2004-10, Vol.64 (19), p.7099-7109 [Periódico revisado por pares]

Philadelphia, PA: American Association for Cancer Research

Texto completo disponível

Citações Citado por
2
Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck
Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck
Material Type:
Artigo 		Adicionar ao Meu Espaço

Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck

LEONARD, C. E ; CHAN, D. C ; CHOU, T.-C ; KUMAR, R ; BUNN, P. A

Cancer research (Chicago, Ill.), 1996-11, Vol.56 (22), p.5198-5204 [Periódico revisado por pares]

Philadelphia, PA: American Association for Cancer Research

Texto completo disponível

Citações Citado por
3
Abstract 4888: Antibody blockade of semaphorin 4D breaks down stromal barriers to enhance tumoricidal immune infiltration, supporting rational immunotherapy combinations
Abstract 4888: Antibody blockade of semaphorin 4D breaks down stromal barriers to enhance tumoricidal immune infiltration, supporting rational immunotherapy combinations
Material Type:
Artigo 		Adicionar ao Meu Espaço

Abstract 4888: Antibody blockade of semaphorin 4D breaks down stromal barriers to enhance tumoricidal immune infiltration, supporting rational immunotherapy combinations

Evans, Elizabeth E. ; Bussler, Holm ; Torno, Sebold ; Mallow, Crystal ; Reilly, Christine ; Scrivens, Maria ; Klimatcheva, Ekaterina ; Winter, Laurie A. ; Kirk, Renee ; Howell, Alan ; Balch, Leslie ; Leonard, John E. ; Paris, Mark ; Fisher, Terrence L. ; Hu-Lieskovan, Siwen ; Ribas, Antoni ; Smith, Ernest S. ; Zauderer, Maurice

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.4888-4888 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
4
Abstract PD1-01: Open-label, randomized, phase 2 study of sapanisertib (TAK-228/MLN0128) in combination with fulvestrant in postmenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor-2-negative (HER2-) advanced or metastatic breast cancer (MBC) that previously progressed during or after aromatase inhibitor therapy (NCT02756364)
Abstract PD1-01: Open-label, randomized, phase 2 study of sapanisertib (TAK-228/MLN0128) in combination with fulvestrant in postmenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor-2-negative (HER2-) advanced or metastatic breast cancer (MBC) that previously progressed during or after aromatase inhibitor therapy (NCT02756364)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Abstract PD1-01: Open-label, randomized, phase 2 study of sapanisertib (TAK-228/MLN0128) in combination with fulvestrant in postmenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor-2-negative (HER2-) advanced or metastatic breast cancer (MBC) that previously progressed during or after aromatase inhibitor therapy (NCT02756364)

García-Saenz, José Á ; Jáñez, Noelia Martínez ; Martin, Miguel ; Martínez, Ainhara Lahuerta ; González-Santiago, Santiago ; Ferrer, Nieves ; Vázquez, Manuel Ramos ; Romero, José Luis Alonso ; Antón, Antonio ; Carrasco, Eva ; Chen, Jingjing ; Neuwirth, Rachel ; Leonard, E Jane ; Slamon, Dennis

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PD1-01-PD1-01 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
5
Abstract CT249: First-in-human study of TAK-500, a novel STING agonist immune stimulating antibody conjugate (ISAC), alone and in combination with pembrolizumab in patients with select advanced solid tumors
Abstract CT249: First-in-human study of TAK-500, a novel STING agonist immune stimulating antibody conjugate (ISAC), alone and in combination with pembrolizumab in patients with select advanced solid tumors
Material Type:
Artigo 		Adicionar ao Meu Espaço

Abstract CT249: First-in-human study of TAK-500, a novel STING agonist immune stimulating antibody conjugate (ISAC), alone and in combination with pembrolizumab in patients with select advanced solid tumors

Diamond, Jennifer R. ; Henry, Jason T. ; Falchook, Gerald S. ; Olszanski, Anthony J. ; Singh, Harshabad ; Leonard, E. Jane ; Gregory, Richard C. ; Appleman, Vicky A. ; Gibbs, John P. ; Harbison, Carole E. ; Li, Cong ; Sapiro, Jessica M. ; Yoneyama, Tomoki ; Parent, Alexander ; Chung, Vincent

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.CT249-CT249 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
6
Abstract LB-156: New-onset cancer cases in FDA’s Sentinel System: A large distributed system of US electronic healthcare data
Abstract LB-156: New-onset cancer cases in FDA’s Sentinel System: A large distributed system of US electronic healthcare data
Material Type:
Artigo 		Adicionar ao Meu Espaço

Abstract LB-156: New-onset cancer cases in FDA’s Sentinel System: A large distributed system of US electronic healthcare data

Haug, Nicole R. ; Wagner, Anita K. ; McGlynn, Katherine A. ; Leonard, Charles E. ; Nguyen, Michael D. ; Major, Jacqueline M.

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.LB-156-LB-156 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
7
Abstract CT086: Interim results from CLASSICAL-Lung, a Phase Ib/II study of VX15/2503 (pepinemab) in combination with avelumab in advanced NSCLC
Abstract CT086: Interim results from CLASSICAL-Lung, a Phase Ib/II study of VX15/2503 (pepinemab) in combination with avelumab in advanced NSCLC
Material Type:
Artigo 		Adicionar ao Meu Espaço

Abstract CT086: Interim results from CLASSICAL-Lung, a Phase Ib/II study of VX15/2503 (pepinemab) in combination with avelumab in advanced NSCLC

Shafique, Michael ; Fisher, Terrence L. ; Evans, Elizabeth E. ; Leonard, John E. ; Pastore, Desa Rae ; Mallow, Crystal ; Smith, Ernest ; Zauderer, Maurice ; Schröeder, Andreas ; Chin, Kevin ; Beck, Thaddeus ; Baumgart, Megan ; Sanborn, Rachel E. ; Goldman, Jonathan W.

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.CT086-CT086 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
8
Abstract CT016: Integrated biomarker trials of VX15/2503 (pepinemab) in combination with checkpoint inhibitors in window of opportunity studies in solid tumors
Abstract CT016: Integrated biomarker trials of VX15/2503 (pepinemab) in combination with checkpoint inhibitors in window of opportunity studies in solid tumors
Material Type:
Artigo 		Adicionar ao Meu Espaço

Abstract CT016: Integrated biomarker trials of VX15/2503 (pepinemab) in combination with checkpoint inhibitors in window of opportunity studies in solid tumors

Lesinski, Gregory B. ; Fisher, Terrence L. ; Evans, Elizabeth E. ; Leonard, John E. ; Pastore, Desa Rae ; Mallow, Crystal ; Smith, Ernest ; Zauderer, Maurice ; Steuer, Conor ; Saba, Nabil F. ; Lowe, Michael ; Kudchadkar, Ragini R. ; Olson, Brian ; Wu, Christina

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.CT016-CT016 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
9
Abstract CT191: Interim results from CLASSICAL-Lung, phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC
Abstract CT191: Interim results from CLASSICAL-Lung, phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC
Material Type:
Artigo 		Adicionar ao Meu Espaço

Abstract CT191: Interim results from CLASSICAL-Lung, phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC

Goldman, Jonathan W. ; Fisher, Terrence L. ; Evans, Elizabeth ; Leonard, John E. ; Pastore, Desa Rae ; Mallow, Crystal ; Smith, Ernest ; Schröeder, Andreas ; Chin, Kevin ; Shafique, Michael ; Beck, Thaddeus ; Baumgart, Megan A. ; Govindan, Ramaswamy ; Gabrail, Nashat ; Sanborn, Rachel E. ; Spira, Alexander I. ; Seetharamu, Nagashree ; Lou, Yanyan ; Mansfield, Aaron S. ; Zauderer, Maurice

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT191-CT191 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
10
Abstract PD1-09: Phase 2 safety and efficacy results of TAK-228 in combination with exemestane or fulvestrant in postmenopausal women with ER-positive/HER2-negative metastatic breast cancer previously treated with everolimus
Abstract PD1-09: Phase 2 safety and efficacy results of TAK-228 in combination with exemestane or fulvestrant in postmenopausal women with ER-positive/HER2-negative metastatic breast cancer previously treated with everolimus
Material Type:
Artigo 		Adicionar ao Meu Espaço

Abstract PD1-09: Phase 2 safety and efficacy results of TAK-228 in combination with exemestane or fulvestrant in postmenopausal women with ER-positive/HER2-negative metastatic breast cancer previously treated with everolimus

Diamond, JR ; Potter, D ; Salkeni, M ; Silverman, P ; Haddad, T ; Forget, F ; Awada, A ; Canon, J-L ; Danso, M ; Lortholary, A ; Bourgeois, H ; Tan-Chiu, E ; Patel, C ; Neuwirth, R ; Leonard, EJ ; Lim, B

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.PD1-09-PD1-09 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Data de Publicação 

De até
Refinar
  1. Antes de1967  (14)
  2. 1967Até1983  (21)
  3. 1984Até1995  (39)
  4. 1996Até2010  (30)
  5. Após 2010  (72)
  6. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.